Additionally, the capacity of GM-CSF to maintain pulmonary function and lung cell-mediated immunity, together with its protective functions in mouse models of influenza, suggest that GM-CSF administration is a possible therapy against COVID-19 (Lang et al., 2020; Trapnell et al., 2019; Rösler and Herold, 2016). The gene discussed is CSF2; the disease is COVID-19.